Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process

Molecular Immunology

Volumn 46, Issue 2, 2008, Pages 225-232

  Hamad, I ^a   Hunter, A C ^a   Szebeni, J ^b,c   Moghimi, S M ^d  

^a UNIVERSITY OF BRIGHTON   (United Kingdom)

^b BAY NANO Research Institute   (Hungary)

^c SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Anaphylatoxins; Anaphylaxis; Complement system; Ficolin MASP 2; Non ionic surfactants; Poly(ethylene glycol); Pseudoallergy

Indexed keywords

CALCIUM; COMPLEMENT; COMPLEMENT COMPONENT BB; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C2; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C4D; COMPLEMENT COMPONENT SC5B 9; COMPLEMENT FACTOR H; FICOLIN; LECTIN; MACROGOL; MANNOSE; MASP 2 ENZYME; N ACETYLGLUCOSAMINE; NAFAMSTAT MESILATE; SERINE PROTEINASE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG SAFETY; DRUG STRUCTURE; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEPLETION;

ADULT; ANTIBODIES; COMPLEMENT PATHWAY, ALTERNATIVE; COMPLEMENT PATHWAY, MANNOSE-BINDING LECTIN; COMPLEMENT SYSTEM PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; HUMANS; MALE; MANNOSE-BINDING PROTEIN-ASSOCIATED SERINE PROTEASES; POLYETHYLENE GLYCOLS; SERUM;

ANIMALIA;

EID: 54849408545     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2008.08.276     Document Type: Article

References (43)

1. Armstrong J.K., Hempel G., Koling S., Chan L.S., Fisher T., Meiselman H.J., and Garratty G. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer 110 (2007) 103-111
2. Asakura S., and Oosawa F. On interaction between 2 bodies immersed in a solution of macromolecules. J. Chem. Phys. 22 (1954) 1255-1256
3. Bhat R., and Timasheff S.N. Steric exclusion is the principal source of the preferential hydration of proteins in the presence of polyethylene glycols. Protein Sci. 1 (1992) 1133-1143
4. Borgens R.B., and Shi R. Immediate recovery from spinal cord injury through molecular repair of nerve membranes with polyethylene glycol. FASEB J. 14 (2000) 27-35
5. Crupi V., Jannelli M.P., Magazu S., Maisano G., Majolino D., Migliardo P., and Pontiero R. Raman spectroscopic study of water in the poly(ethylene glycol) hydration shell. J. Mol. Struct. 381 (1996) 207-212
6. Fujita T. Evolution of lectin-complement pathway and its role in innate immunity. Nat. Rev. Immunol. 2 (2002) 346-353
7. Fujita T., Gigli I., and Nussenzweig V. Human C4-binding protein. II. Role in proteolysis of C4b by C3b inactivator. J. Exp. Med. 148 (1978) 1044-1051
8. Hamad I., Hunter A.C., Rutt K.J., Liu Z., Dai H., and Moghimi S.M. Complement activation by PEGylated single-walled carbon nanotubes is independent of C1q and alternative pathway turnover. Mol. Immunol. 45 (2008) 3797-3803
9. Harris J.M., and Chess R.B. Effect of PEGylation on pharmaceuticals. Nat. Rev. Drug Discov. 2 (2003) 214-221
10. Hattori R., Hamilton K.K., McEver R.P., and Sims P.J. Complement proteins C5b-9 induce secretion of high molecular-weight multimers of endothelial von Willebrand-factor and translocation of granule membrane-protein GMP-140 to the cell-surface. J. Biol. Chem. 264 (1989) 9053-9060
11. Ingram D.A., Forman M.B., and Murray J.J. Activation of complement by Fluosol attributes to the Pluronic detergent micelle structure. J. Cardiovasc. Pharmacol. 22 (1993) 456-461
12. Ito B.R., Engler R.L., and Del Balzo U. Role of cardiac mast cells in complement C5a-induced myocardial ischemia. Am. J. Physiol. Heart Circ. Physiol. 264 (1993) H1346-H1354
13. Jack D.L., Jarvis G.A., Booth C.L., Turner M.W., and Klein N.J. Mannose-binding lectin accelerates complement activation and increases serum killing of Nisseria meningitids serogroup C. J. Infec. Dis. 184 (2001) 836-845
14. Kent K.M., Cleman M.W., Cowley M.J., Forman M.B., Jaffe C.C., Kaplan M., King S.B., Krucoff M.W., Lassar T., Mcauley B., Smith R., Wisdom C., and Wohlgelernter D. Reduction of myocardial ischemia during percutaneous coronary angioplasty with oxygenated Fluosol. Am. J. Cardiol. 66 (1990) 279-284
15. Koob A.O., and Borgens R.B. Polyethylene glycol treatment after traumatic brain injury reduces β-amyloid precursor protein accumulation in degenerating axons. J. Neurosci. Res. 83 (2006) 1558-1563
16. Kozielski M. Conformational changes in the chains of polyoxyethyleneglycols. J. Mol. Liquid 128 (2006) 105-107
17. Krarup A., Thiel S., Hansen A., Fujita T., and Jensenius J.C. L-ficolin is a pattern recognition molecule specific for acetyl groups. J. Biol. Chem. 279 (2004) 47513-47519
18. Lambris J.D., Ricklin D., and Geisbrecht B.V. Complement evasion by human pathogens. Nat. Rev. Microbiol. 6 (2008) 132-142
19. Laverty P.H., Leskovar A., Breur G.J., Coates J.R., Bergman R.L., Widmer W.R., Toombs J.P., Shapiro S., and Borgens R.B. A preliminary study of intravenous surfactants in paraplegic dogs: polymer therapy in canine clinical SCI. J. Neurotrauma 21 (2004) 1767-1777
20. Lee R.T., Ichikawa Y., Fay M., Drickamer K., Shao M.C., and Lee Y.C. Ligand-binding characteristics of rat serum-type mannose-binding protein (MBP-A): homology of binding site architecture with mammalian and chicken hepatic lectins. J. Biol. Chem. 266 (1991) 4810-4815
21. Marone G., Patella V., de Crescenzo G., Genovese A., and Adt M. Human heart mast cells in anaphylaxis and cardiovascular disease. Int. Arch. Allergy Immunol. 107 (1995) 72-75
22. Moghimi S.M., Hamad I., Andresen T., Jørgensen K., and Szebeni J. Methylation of the phosphate oxygen moiety of phospholipid-methoxy(polyethylene glycol) conjugate prevents PEGylated liposome-mediated complement activation and anaphylatoxin production. FASEB J. 20 (2006) E2057-E2067
23. Moghimi S.M., Hunter A.C., Dadswell C.M., Savay S., Alving C.R., and Szebeni J. Causative factors behind poloxamer 188 (Pluronic F68.Flocor™)-induced complement activation in human sera. A protective role against poloxamer-mediated complement activation by elevated serum lipoprotein levels. Biochim. Biophys. Acta Mol. Basis Dis. 1689 (2004) 103-113
24. Moore Jr. F.D., Austen K.F., and Fearon D.T. Antibody restores human alternative complement pathway activation by mouse erythrocytes rendered functionally deficient by pre-treatment with pronase. J. Immunol. 128 (1982) 1301-1306
25. Pangburn M.K., Schriber R.D., and Muller-Eberhard H.J. Human complement C3b-inactivator-isolation, characterization and demonstration of an absolute requirement for serum protein beta-1H for cleavage of C3b and C4b in solution. J. Exp. Med. 146 (1977) 257-270
26. Pfeifer P.H., Kawahara M.S., and Hugli T.E. Possible mechanism for in vitro complement activation in blood and plasma samples: Futhan/EDTA controls in vitro complement activation. Clin. Chem. 45 (1999) 1190-1199
27. Police A.M., Waxman K., and Tominaga G. Pulmonary complications after Flusol administration to patients with life-threatening blood loss. Crit. Care Med. 13 (1985) 96-98
28. Richter A.W., and Akerblom E. Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors. Int. Arch. Allergy Appl. Immunol. 70 (1984) 124-131
29. Scharfstein J., Ferreira A., Gigli I., and Nussenzweig V. Human C4-binding protein. I. Isolation and characterization. J. Exp. Med. 148 (1978) 207-222
30. Szebeni J. Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. Toxicology 216 (2005) 106-121
31. Szebeni J., Baranji L., Sávay S., Bodó M., Milosevits J., Alving C.R., and Bünger R. Complement activation-related cardiac anaphylaxis in pigs: role of C5a anaphylatoxin and adenosine in liposome-induced abnormalities in ECG and heart function. Am. J. Physiol. Heart Circ. Physiol. 290 (2006) H1050-1058
32. Szebeni J., Muggia F.M., and Alving C.R. Complement activation by cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J. Natl. Cancer Inst. 90 (1998) 300-306
33. Szebeni J., Wassef N.M., Hartman K.R., Rudolph A.S., and Alving C.R. Complement activation in vitro by the red cell substitute, liposome-encapsulated hemoglobin: mechanism of activation and inhibition by soluble complement receptor type 1. Transfusion 37 (1997) 150-159
34. Szebeni J., Wassef N.M., Spielberg H., Rudolph A.S., and Alving C.R. Complement activation in rats by liposomes and liposome-encapsulated hemoglobin: evidence for anti-lipid antibodies and alternative pathway activation. Biochem. Biophys. Res. Commun. 205 (1994) 255-263
35. Tardieu A., Bonneté F., Finet S., and Vivarès D. Understanding salt or PEG induced attractive interactions to crystallize biological macromolecules. Acta Crystalogr. D58 (2002) 1549-1553
36. Tasaki K. Poly(oxyethylene)-water interactions: a molecular dynamic study. J. Am. Chem. Soc. 118 (1996) 8459-8469
37. Tremper K.K., Friedman A.E., Levine E.M., Lapin R., and Camarillo D. The preoperative treatment of severely anemic patients with a perfluorochemical oxygen-transport fluid, Fluosol-DA. N. Engl. J. Med. 12 (1984) 428-431
38. Vercellotti G.M., Hammerschmidt D.E., Craddock P.R., and Jacob H.S. Activation of plasma complement by perfluorocarbon artificial blood: probable mechanism of adverse pulmonary reactions in treated patients and rationale for corticosteroid prophylaxis. Blood 59 (1982) 1299-1304
39. Wallis R. The lectin-pathway of complement activation: MBL, other collectins and ficolins. Immunobiology 205 (2002) 433-445
40. Walport M.J. Advances in immunology: complement (first of two parts). N. Engl. J. Med. 344 (2001) 1058-1066
41. Walport M.J. Advances in immunology: complement (second of two parts). N. Engl. J. Med. 344 (2001) 1140-1144
42. Weis W.I., Drickamer K., and Hendrickson W.A. Structure of a C-type mannose-binding protein complexed with an oligosaccharide. Nature 360 (1992) 127-134
43. Yamaoka T., Tabata Y., and Ikada Y. Distribution and tissue uptake of poly(ethyleneglycol) with different molecular-weights after intravenous administration to mice. J. Pharm. Sci. 83 (1994) 601-604